Bio-Rad Laboratories, Inc. (NYSE:BIO) has been given a consensus broker rating score of 0.00 () from the two analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and one has assigned a strong buy rating to the company.
Analysts have set a 12 month consensus price target of $230.00 for the company and are expecting that the company will post $0.27 EPS for the current quarter, according to Zacks. Zacks has also given Bio-Rad Laboratories an industry rank of 182 out of 265 based on the ratings given to related companies.
BIO has been the topic of a number of analyst reports. Zacks Investment Research lowered shares of Bio-Rad Laboratories from a “hold” rating to a “sell” rating in a research report on Thursday, January 5th. Deutsche Bank AG reiterated a “hold” rating and issued a $195.00 price objective on shares of Bio-Rad Laboratories in a research report on Wednesday, January 18th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $225.00 price objective on shares of Bio-Rad Laboratories in a research report on Sunday, December 4th.
Shares of Bio-Rad Laboratories (NYSE:BIO) opened at 200.41 on Monday. The stock has a market cap of $5.93 billion, a price-to-earnings ratio of 210.96 and a beta of 0.89. Bio-Rad Laboratories has a 12-month low of $132.29 and a 12-month high of $209.50. The stock’s 50 day moving average is $195.03 and its 200-day moving average is $177.84.
Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Thursday, February 23rd. The company reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of $1.03 by $1.73. Bio-Rad Laboratories had a net margin of 4.75% and a return on equity of 3.79%. The firm earned $571.45 million during the quarter, compared to analysts’ expectations of $574.40 million. During the same quarter last year, the business earned $1.68 earnings per share. The business’s quarterly revenue was up .1% on a year-over-year basis. Equities analysts anticipate that Bio-Rad Laboratories will post $2.80 EPS for the current fiscal year.
In other Bio-Rad Laboratories news, EVP Michael Crowley sold 300 shares of the firm’s stock in a transaction on Tuesday, March 7th. The stock was sold at an average price of $196.13, for a total value of $58,839.00. Following the completion of the sale, the executive vice president now owns 2,760 shares of the company’s stock, valued at $541,318.80. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 28.38% of the stock is currently owned by company insiders.
A number of large investors have recently added to or reduced their stakes in BIO. Oregon Public Employees Retirement Fund increased its stake in Bio-Rad Laboratories by 2.1% in the third quarter. Oregon Public Employees Retirement Fund now owns 7,125 shares of the company’s stock worth $1,167,000 after buying an additional 144 shares during the period. Fisher Asset Management LLC increased its stake in Bio-Rad Laboratories by 3.1% in the third quarter. Fisher Asset Management LLC now owns 290,416 shares of the company’s stock worth $47,573,000 after buying an additional 8,833 shares during the period. Creative Planning increased its stake in Bio-Rad Laboratories by 14.0% in the third quarter. Creative Planning now owns 1,007 shares of the company’s stock worth $165,000 after buying an additional 124 shares during the period. BTR Capital Management Inc. acquired a new stake in Bio-Rad Laboratories during the third quarter worth approximately $523,000. Finally, Hermes Investment Management Ltd. increased its stake in Bio-Rad Laboratories by 7.5% in the third quarter. Hermes Investment Management Ltd. now owns 268,432 shares of the company’s stock worth $43,972,000 after buying an additional 18,814 shares during the period. 64.29% of the stock is owned by institutional investors.
WARNING: This piece was reported by Web Breaking News and is the sole property of of Web Breaking News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at http://www.webbreakingnews.com/2017/03/25/bio-rad-laboratories-inc-bio-given-230-00-average-target-price-by-brokerages.html.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.